| Document Date: 2011-01-14 08:24:41 Open Document File Size: 674,24 KBShare Result on Facebook
Company HDL / TG / Author’s Treatment / Greater / Weight / At / / Continent North America / Europe / / Country United States / / / Facility PGY1 Community Pharmacy Resident University of Texas College / / IndustryTerm mg/d / 20mg/d / obesity treatment / therapies for obesity / Decreases food intake / rimonabant groups / 20mg/d rimonabant / energy / study‐site / sustained negative energy / rimonabant treatment groups / food intake / Treatment of Obesity / / MedicalCondition artherogenic dyslipidemia / untreated dyslipidemia / Obesity Bailey i. b / Obesity Bailey D. RIO / inflammatory markers / Obesity Trials A. RIO / obesity / Obesity Bailey B. RIO / cardiac arrest / Non‐fatal stroke / endocrine disorders / Obesity Bailey I. What / Obesity Bailey V. VI / Hypertension / substantial endocrine disease / Cancer / chronic obesity / Obesity Bailey X. Rimonabant / Dyslipidemia / American Epidemic / dyslipidemias / obesity A. Fluoxetine / Diabetes / cardiovascular / pulmonary disease / Heart disease C. Mechanical / metabolic syndrome / diabetes mellitus / Non‐fatal heart attack / psychological disorders / Obesity Epidemic Obesity / inflammation / thrombosis / depression / Obesity Bailey C. RIO / / MedicalTreatment contraception / Resuscitation / Pharmacotherapy / / Organization University of Texas College of Pharmacy/H‐E‐B Pharmacy Residency / FDA / / Person James Weems / Van Gaal / R. Bailey / / Position Director / / Product Topiramate / Byetta / Zoloft / Zonisamide / Prozac / Didrex / Topamax / Tenuate / Meridia / Wellbutrin / Fluoxetine / Xenical / TC / Lamotrigine / Glucophage / Symlin / Alli / Lamictal / / ProvinceOrState District of Columbia / Mississippi / Colorado / / Region North America / South America / / URL http /
SocialTag |